Nodule and lipoma formation can occur rarely after an intramuscular influenza vaccination, particularly when administered ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen ...
A 10-day low-dose Dacogen regimen showed a 33% response rate in myelofibrosis patients, with a median response duration of seven months. High prognostic scores, elevated fetal hemoglobin, and reduced ...
The FDA has granted accelerated approval to subcutaneous treatment with mosunetuzumab (Lunsumio VELO™), a CD20xCD3 bispecific antibody, for adult patients with relapsed or refractory follicular ...
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Authors retain all rights in any data supplements associated ...
Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences Approval supported by data demonstrating compelling complete response rate in third-line or ...
The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or ...
In a preclinical breakthrough that could transform cell therapies for incurable diseases, researchers at Sinai Health and the University of Toronto have developed a technology that may one day ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback